Lifecare presentation at the Diabetes Technology Meeting 2024.

14 Oct 2024 07:05 CEST

Bergen, Norway, October 14, 2024: Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM) will present a poster at the Diabetes Technology Meeting (DTM)
in Burlingame, California, an international diabetes technology conference
hosted by the Diabetes Technology Society.

As the DTM returns as a face-to-face meeting after three years of virtual
set-up, Lifecare is pleased to be present at the conference to present a
poster presentation on October 16th with the title "Continuous Glucose
Monitoring with an Osmotic-Pressure Based Continuous Glucose Sensor -- Human
Pilot Study Results and Next Development Steps".

The results from Lifecare's clinical study LFC-SEN-001 has previously been
presented at the American Diabetes Association Scientific Sessions (ADA) in
San Diego, CA, USA, in June 2023, and with additional data at the virtual DTM
2023. At the upcoming event Lifecare will in addition present ongoing and
upcoming development steps in the longevity study LFC-SEN-002.

The clinical study data presented at the ADA 2023 and DTM 2023 included the
technology proof-of-concept in human tissue, as well as confirmation that
Lifecare's CGM system Sencell has a solid clinical accuracy. The initial data
from Lifecare's ongoing longevity study LFC-SEN-002 has confirmed a 12-week
operational sensor lifetime in live tissue, without any unexpected tissue
reactions.

From the clinical study data, Lifecare calculated a Mean Absolute Relative
Difference (MARD) value of 9,6%. In context, regulatory authorities expect a
MARD below 10% to acknowledge CGMs for therapeutic (medical) decisions, such
as insulin dose adjustments. In comparison, the MARD of glucose measurements
in capillary blood (Blood Glucose Monitoring -- BGM), representing the gold
standard for patient self-monitoring of glucose, are in the range 5-10%.

The Sencell MARD calculated in 2023 indicates accuracy comparable with
commercially available CGM systems.

On October 10th, 2024, Lifecare announce that the company's next human study
protocol has been internally concluded, with the aim to progress the clinical
sensor development towards regulatory approval.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

629499_Lifecare presentation at the Diabetes Technology Meeting 2024..pdf